Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 99, Issue 3, Pages 285-297Publisher
WILEY
DOI: 10.1002/cpt.318
Keywords
-
Categories
Funding
- National Institute of General Medical Sciences of the National Institutes of Health [R01GM079719]
Ask authors/readers for more resources
The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and clinical research have dramatically increased the types of data available to the public. The past few years have witnessed successful use of big data in many sectors across the whole drug discovery pipeline. In this review, we will highlight the state of the art in leveraging big data to identify new targets, drug indications, and drug response biomarkers in this era of precision medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available